Moderna
Moderna, Inc. (Nasdaq: MRNA) develops, manufactures and commercializes medicines based on messenger RNA (mRNA), a technology used to instruct cells to produce proteins. Its commercial products include Spikevax and mNEXSPIKE, COVID-19 vaccines, and mRESVIA, a vaccine for respiratory syncytial virus (RSV); its customers… From the company’s description.
In fiscal 2025, Moderna reported revenue of $1.94B, down 39.9% from fiscal 2024, and a net loss of $2.82B. Its operating margin was −158.1%, and operations used $1.87B in cash. Over the twelve months to Jun 30, 2026, revenue was $2.23B.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Moderna does
In the company’s own words
Moderna, Inc. (Nasdaq: MRNA) develops, manufactures and commercializes medicines based on messenger RNA (mRNA), a technology used to instruct cells to produce proteins. Its commercial products include Spikevax and mNEXSPIKE, COVID-19 vaccines, and mRESVIA, a vaccine for respiratory syncytial virus (RSV); its customers and end users include healthcare providers and people receiving vaccines. The company also develops vaccine and therapeutic candidates for infectious diseases, cancer and rare diseases, including individualized neoantigen therapy intismeran autogene, developed with Merck. Its pipeline comprises 35 therapeutic and vaccine programs, including six in late-stage development. Moderna organizes its research and development around three franchises: infectious disease vaccines, oncology therapeutics and rare disease therapeutics. The company uses a platform combining mRNA design, delivery technologies such as lipid nanoparticles, and manufacturing processes. It operates a global manufacturing network, including facilities in the United States, United Kingdom, Canada and Australia. Moderna reported total revenue of $1.9 billion in fiscal 2025, largely from sales of its COVID-19 vaccines.
Company details
- Sector
- Health Care
- Industry (SIC)
- Biological Products
- Headquarters
- CAMBRIDGE, MA
- Fiscal year end
- December
- CIK
- 1682852
- SIC
- 2836
Financial performance, year by year
Fiscal 2018–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Moderna — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Moderna’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Moderna and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Moderna's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Moderna's last four quarterly filings that the numbers alone won't show?”